Watching a parent or patient spend two decades in "managed decline" isn't a medical triumph; it's a failure of imagination. We've gotten very good at stretching out the end of the survival curve, even as the quality of that life frays into nothing. My work in lysosomal proteostasis centers on a specific mechanical tipping point. When a cell can no longer burn through its own errors, it stops functioning and starts acting as a storage unit for its own history. That's where the real "first diagnosis" happens. It isn't some sudden catastrophe; it's the slow, quiet saturation of the lysosomal-autophagic pathway.

Focusing solely on lifespan feels like we're just subsidizing a longer stay in the waiting room. If we pivot to reversibility—specifically restoring TFEB-mediated clearance—we’re aiming for what I call Architectural Forgiveness. We should be aiming for a biology that can actually forget its own damage. By the time a chronic condition is caught, cellular debris has already rewritten the architecture of the body. Reversing aging isn't about mere survival. It’s about stopping the self from being overwritten by metabolic waste.

Why are we still obsessed with death as an endpoint in clinical trials? Death's an event, but the loss of biological agency is a process that takes decades. We've got to fund tools that restore the "clean slate." I'm talking about small molecule TFEB activators and nuclear-pore stabilizers that help the cell remember how to take out the trash. Adding more years in the dark doesn't help anyone. We need mechanisms that keep the lights on until the end. I’m looking for collaborators who prioritize dynamic clearance assays over static survival markers. If we can't empty the incinerator, we’re just building longer hallways in a burning building.